Speaker - Barry Bunin

 Barry  Bunin  Thumbnail


Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen over $20 million in business transactions. Prior to CDD, Dr. Bunin was an Entrepreneur in Residence with Eli Lilly & Co. Before that he was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, Dr. Bunin led a team that integrated exhaustive reaction capture (synthetic chemistry) with gene-family wide SAR capture (medicinal chemistry).

On the scientific side, he co-authored Chemoinformatics: Theory, Practice, and Products (Springer-Verlag), a text that overviews modern chemoinformatics technologies, and The Combinatorial Index (Academic Press), a widely used text on high-throughput chemical synthesis. In the lab, Dr. Bunin did medicinal synthetic chemistry developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals (now Celera) and RGD mimics to inhibit GP-IIbIIIa at Genentech. Dr. Bunin is on a patent for Carfilzomib--a selective proteasome inhibitor now in phase 3 clinical trials for multiple myeloma.

Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.

1 Program

Opening the Sources of Drug Discovery

10.23.11 | 01:39:23 min | 0 comments